Abstract
Respiratory syncytial virus (RSV) is the most significant cause of pediatric respiratory infections. Palivizumab (Synagis®), a humanized monoclonal antibody, has been used successfully for a number of years to prevent severe RSV disease in at-risk infants. However, despite intense efforts, there is no approved vaccine or small molecule drug for RSV. As an enveloped virus, RSV must fuse its envelope with the host cell membrane, which is accomplished through the actions of the fusion (F) glycoprotein, with attachment help from the G glycoprotein. Because of their integral role in initiation of infection and their accessibility outside the lipid bilayer, these proteins have been popular targets in the discovery and development of antiviral compounds and vaccines against RSV. This review examines advances in the development of antiviral compounds and vaccine candidates.
Keywords: Antiviral, attachment glycoprotein, fusion glycoprotein, respiratory syncytial virus, therapeutic, vaccine, antiviral drug
Infectious Disorders - Drug Targets
Title:Targeting RSV with Vaccines and Small Molecule Drugs
Volume: 12 Issue: 2
Author(s): Heather M. Costello, William C. Ray, Supranee Chaiwatpongsakorn and Mark E. Peeples
Affiliation:
Keywords: Antiviral, attachment glycoprotein, fusion glycoprotein, respiratory syncytial virus, therapeutic, vaccine, antiviral drug
Abstract: Respiratory syncytial virus (RSV) is the most significant cause of pediatric respiratory infections. Palivizumab (Synagis®), a humanized monoclonal antibody, has been used successfully for a number of years to prevent severe RSV disease in at-risk infants. However, despite intense efforts, there is no approved vaccine or small molecule drug for RSV. As an enveloped virus, RSV must fuse its envelope with the host cell membrane, which is accomplished through the actions of the fusion (F) glycoprotein, with attachment help from the G glycoprotein. Because of their integral role in initiation of infection and their accessibility outside the lipid bilayer, these proteins have been popular targets in the discovery and development of antiviral compounds and vaccines against RSV. This review examines advances in the development of antiviral compounds and vaccine candidates.
Export Options
About this article
Cite this article as:
M. Costello Heather, C. Ray William, Chaiwatpongsakorn Supranee and E. Peeples Mark, Targeting RSV with Vaccines and Small Molecule Drugs, Infectious Disorders - Drug Targets 2012; 12 (2) . https://dx.doi.org/10.2174/187152612800100143
DOI https://dx.doi.org/10.2174/187152612800100143 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Signal Transduction Pathways Provide Opportunities to Enhance HDL and apoAI-Dependent Reverse Cholesterol Transport
Current Pharmaceutical Biotechnology Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer’s Disease
Current Alzheimer Research Experimental and Theoretical Study on the Electrochemical Behavior of Zofenopril and its Voltammetric Determination
Current Pharmaceutical Analysis Application of Current Diagnostic Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy in Every Day Clinical Practice
Current Pharmaceutical Design Recent Patents on Rho Signaling Pathway as Therapeutic Target for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Genetic and Non-genetic Determinants of Cardiovascular Disease in South Asians
Current Diabetes Reviews Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry The Effect of Stress Management Program on Perceived Stress in Patients with Type 2 Diabetes: A Randomized Controlled Trial
Current Diabetes Reviews Pharmacotherapy for Intermittent Claudication: From Consensus-Based to Evidence-Based Treatment
Vascular Disease Prevention (Discontinued) Human Complex Trait Genetics: Lifting the Lid of the Genomics Toolbox - from Pathways to Prediction
Current Genomics Current Therapeutic Concepts in Peripartum Cardiomyopathy
Current Pharmaceutical Design Discovery of Small Molecule Inhibitors for Prevention of Complement- Mediated Immune Hemolysis
Drug Design Reviews - Online (Discontinued) Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies
Current Alzheimer Research Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry Hematopoietic Progenitor and Stem Cells Circulate by Surfing on Intracellular Ca2+ Waves: A Novel Target for Cell-based Therapy and Anti-cancer Treatment?
Current Signal Transduction Therapy CD147: A Novel Modulator of Inflammatory and Immune Disorders
Current Medicinal Chemistry Therapeutic Effects of Physical Exercise and the Mesenchymal Stem Cell Secretome by Modulating Neuroinflammatory Response in Multiple Sclerosis
Current Stem Cell Research & Therapy Left Ventricular Non-compaction: From Recognition to Treatment
Current Pharmaceutical Design Potential Role for Dendritic Cells in Endothelial Dysfunction, Diabetes and Cardiovascular Disease
Current Pharmaceutical Design Co-administration of Phycocyanobilin and/or Phase 2-Inducer Nutraceuticals for Prevention of Opiate Tolerance
Current Pharmaceutical Design